SCHEMBL20535219

SCHEMBL20535219

O=C(O)N1CCCC1CN(CCO)Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ HRH3 Q9Y5N1 3/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ GABRA1 P14867 1/20 0.42
▸ GABRG2 P18507 1/20 0.42
▸ GABRB3 P28472 1/20 0.42
▸ GABRA3 P34903 1/20 0.42
▸ GABRA2 P47869 1/20 0.42
▸ GABRB2 P47870 1/20 0.42
▸ MEN1 O00255 4/20 0.40
▸ KMT2A Q03164 4/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ GAA P10253 1/20 0.39
▸ DPP7 Q9UHL4 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ SPHK2 Q9NRA0 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28472037 0.96 KDM4E (0.49) KDM4EHSD17B10HRH3KCNH2GABRA1
SCHEMBL21216231 0.84 JAK2 (0.44) KDM4EHSD17B10HRH3KCNH2MEN1
SCHEMBL21216112 0.84 JAK2 (0.44) KDM4EHSD17B10HRH3KCNH2MEN1
SCHEMBL20535067 0.84 KDM4E (0.37) KDM4EHSD17B10HRH3KCNH2GAA
SCHEMBL21216118 0.81 KDM1A (0.46) KDM4EHSD17B10HRH3KCNH2MEN1
SCHEMBL5046253 0.79 CYP1A2 (0.40) HRH3ALDH1A1LMNA
SCHEMBL21216241 0.79 KDM4E (0.51) KDM4EHSD17B10HTT
SCHEMBL20535908 0.78 LMNA (0.41) KDM4EHRH3KCNH2MEN1KMT2A
SCHEMBL6541558 0.76 ALDH1A1 (0.39) ALDH1A1
SCHEMBL23459127 0.75 SCD5 (0.57) HRH3GABRA1GABRG2GABRB3GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199681-A1 OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS EVONETIX LTD (GB) 2024-06-20 — — US disclosed
US-11161869-B2 Thermally-cleavable protecting and linker groups EVONETIX LTD. (GB) 2021-11-02 — — US disclosed
US-20210107934-A1 THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS SILICON VALLEY BANK 2021-04-15 — — US disclosed
US-20210047361-A1 OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS SILICON VALLEY BANK 2021-02-18 — — US disclosed
EP-3743433-A1 OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS Evonetix Ltd (GB) 2020-12-02 — — EP disclosed
CN-111770928-A Synthesis of oligonucleotides and nucleic acids 埃万奈蒂克有限公司 2020-10-13 — — CN disclosed
WO-2019145713-A9 OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS EVONETIX LTD (GB) 2020-08-06 — — WO disclosed
EP-3609866-A1 THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS Evonetix Ltd (GB) 2020-02-19 — — EP disclosed
WO-2019145713-A1 OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS EVONETIX LTD (GB) 2019-08-01 — — WO disclosed
WO-2018189546-A1 THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS EVONETIX LTD (GB) 2018-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199681-A1 OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS POLN, POLI, ADAR KDM4E 4074/4885HSD17B10 3035/4885HRH3 4134/4885
US-20210107934-A1 THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS CTDSP1, RNGTT, SSU72 KDM4E 2740/4885HSD17B10 4510/4885HRH3 2670/4885
US-20210047361-A1 OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS POLN, POLI, ADAR KDM4E 4074/4885HSD17B10 3035/4885HRH3 4134/4885
US-11161869-B2 Thermally-cleavable protecting and linker groups CTDSP1, RNGTT, SSU72 KDM4E 2740/4885HSD17B10 4510/4885HRH3 2670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback